Tecentriq-Abraxane Combo Prolonging Survival in TNBC Patients, Phase 3 Trial Data Show
News
Tecentriq in combination with Abraxane, a chemotherapy, continues to prolong overall survival in adults with triple-negative breast cancer (TNBC) who test positive for the PD-L1 factor, a new interim analysis from ... Read more